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Abstract
Background: A large proportion of patients with autosomal dominant polycystic kidney disease (ADPKD) suffers
from polycystic liver disease. Symptoms arise when liver volume increases. The somatostatin analogue lanreotide
has proven to reduce liver volume in patients with polycystic liver disease. However, this study also included
patients with isolated polycystic liver disease (PCLD). The RESOLVE trial aims to assess the efficacy of lanreotide
treatment in ADPKD patients with symptomatic polycystic livers. In this study we present the design of the
RESOLVE trial.
Methods/design: This open-label clinical trial evaluates the effect of 6 months of lanreotide in ADPKD patients
with symptomatic polycystic livers. Primary outcome is change in liver volume determined by computerised
tomography-volumetry. Secondary outcomes are changes in total kidney volume, kidney intermediate volume and
renal function. Furthermore, urinary (NGAL, a1-microglobulin, KIM-1, H-FABP, MCP-1) and serum (fibroblast growth
factor 23) biomarkers associated with ADPKD disease severity are assessed to investigate whether these biomarkers
predict treatment responses to lanreotide. Moreover, safety and tolerability of the drug in ADPKD patients will be
assessed.
Discussion: We anticipate that lanreotide is an effective therapeutic option for ADPKD patients with symptomatic
polycystic livers and that this trial aids in the identification of patient related factors that predict treatment
response.
Trial registration number: Clinical trials.gov NCT01354405
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Background
Autosomal dominant polycystic kidney disease (ADPKD)
most often presents a kidney phenotype with hyperten-
sion and renal failure due to continuous growth of renal
cysts. It affects all ethnic groups and has an incidence of
1:500 to 1:1000 [1]. ADPKD is inherited in an autosomal
dominant fashion, and so far two genes, PKD1 and
PKD2, have been implicated to cause the disease [2].
A large proportion of ADPKD patients suffers from
polycystic liver disease, often while renal function capa-
city is preserved [3] The natural course of polycystic
liver disease dictates a continuous progression of size
and number of hepatic cysts [4,5]. The rate of progres-
sion is still unknown at his time, but recent trials
showed that liver volume increases with 0.9-1.6% within
one year [6-8].
Most ADPKD patients with polycystic liver disease are
asymptomatic until significant hepatomegaly develops.
Subsequently mechanical complaints such as abdominal
distension, pain, and early satiety arise [9,10]. Other
complications include intracystic hemorrhage or rupture
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able treatment options aim at reduction of liver volume
and are mainly surgical [11]. However, drawbacks of
surgical therapy are the partial effectiveness, their inher-
ent morbidity and mortality and their inability to change
the natural course of the disease.
This has led to the introduction of somatostatin analo-
gues as a medical treatment option for polycystic liver dis-
ease. Somatostatin analogues, such as lanreotide and
octreotide, are thought to decrease polycystic liver volume
through their virtue of cAMP repression [12,13]. We
recently performed a trial with the somatostatin analogue
lanreotide in polycystic liver patients with autosomal
dominant polycystic liver disease (PCLD; isolated polycys-
tic liver disease) or ADPKD [8]. In this trial, 54 patients
were randomly assigned to lanreotide or placebo and trea-
ted for 6 months. Lanreotide decreased liver volume with
2.9%, while it increased by 1.6% with placebo. Moreover,
there was a trend of delayed growth of polycystic kidney
volume in the 32 ADPKD patients that participated.
Others trials showed similar effects in reducing polycystic
liver volume with octreotide [6,7,14]. These observations
clearly support the thesis that polycystic liver volume can
be reduced by somatostatin analogues.
H o w e v e r ,t h em a j o r i t yo ft h e s et r i a l si n c l u d e dam i x -
ture of ADPKD and PCLD patients. It is still unknown
if these patient groups have divergent responses to treat-
ment with somatostatin analogues. To eliminate this
possible confounding factor, we have designed and
initiated a clinical trial (RESOLVE trial) to examine the
effectiveness (change in total liver volume) of lanreotide
in ADPKD patients with polycystic livers. In addition,
we will determine the effect of lanreotide on change in
total kidney and kidney intermediate volume. Intermedi-
ate volume is tightly correlated with glomerular filtra-
tion rate (GFR) and its long-term decline, and may
represent a marker for ADPKD progression [15]. Finally,
multiple sets of urinary (NGAL, a1-microglobulin,
KIM-1, H-FABP, MCP-1) and plasma (fibroblast growth
factor 23 (FGF23)) biomarkers have been discovered
that are correlated to parameters of ADPKD disease
severity, and may be associated with treatment response
to lanreotide [16,17]. In conclusion, using the dataset
that is generated by the RESOLVE trial, we want to
assess (1) whether lanreotide has a beneficial effect on
growth of polycystic liver volume, (2) on growth of total
kidney and intermediate volume, (3) on renal function,
and (4) whether the suggested biomarkers predict treat-
ment responses to lanreotide.
Methods/design
Study aim
The primary objective of the RESOLVE trial is to deter-
mine the effectiveness of lanreotide to attenuate growth
of liver volume in ADPKD patients with symptomatic
polycystic livers. ADPKD patients with polycystic livers
will receive lanreotide 120 mg every 4 weeks for a total
of 24 weeks (Figure 1). Secondary objectives are to
assess the effect of lanreotide treatment on total kidney
and kidney intermediate volume, to follow renal func-
tion and to identify biomarkers that predict treatment
response. Finally, safety and tolerability of lanreotide
treatment in ADPKD patients will also be assessed.
Study population
ADPKD patients with symptomatic polycystic liver dis-
ease Gigot type II (diffuse medium-size cysts; hepatic
parenchyma preserved) or Gigot type III (massive, dif-
fuse small- and medium-size cysts; little hepatic par-
enchyma preserved) between 18 and 70 years are
eligible for participation of the study [18]. Symptomatic
patients are defined as having at least three of the fol-
lowing symptoms:
￿ Abdominal pain
￿ Abdominal distension
￿ Abdominal fullness
￿ Dyspnoea
￿ Early Satiety
￿ Back pain
￿ Nausea or vomiting
￿ Anorexia
￿ Weight loss
￿ Jaundice
The diagnosis of ADPKD is based upon the Ravine
criteria [19]. Furthermore, patients must have an esti-
mated glomerular filtration rate (eGFR) by the Modifica-
tion of Diet in Renal Disease (MDRD) above 30 ml/min/
1.73 m
2 [20]. The specific study inclusion and exclusion
criteria are listed below.
Figure 1 RESOLVE trial profile. ADPDK subjects are screened for
eligibility, and 43 ADPKD patients with symptomatic polycystic liver
disease and eGFR > 30 ml/min (MDRD formula) will be included. At
day 1, all patients undergo CT volumetry of liver and kidneys.
Patients without polycystic type II or III livers, as determined with CT
volumetry, will be excluded from the study. Interval visits are
scheduled 4 and 12 weeks after start of treatment. After 24 weeks
of treatment with lanreotide (6 injections), another CT will be
performed to evaluate the change in liver and kidney volume.
Gevers et al. BMC Nephrology 2012, 13:17
http://www.biomedcentral.com/1471-2369/13/17
Page 2 of 7Inclusion criteria
￿ Age 18 to 70 years
￿ Adult subjects with a diagnosis of ADPKD and at
least a symptomatic polycystic liver Gigot type II[18]
￿ eGFR > 30 ml/min/1.73 m
2 (MDRD formula) at
screening
￿ S u b j e c t sa r ew i l l i n ga n da b l et oc o m p l yw i t ht h e
study drug regimen and all other study requirements
￿ Signed informed consent
Exclusion criteria
￿ History of renal transplantation
￿ Use of oral contraceptives or estrogen suppletion
￿ Pregnancy or breastfeeding
￿ History of cardiac or pulmonary disease, sympto-
matic gallstones, pancreatitis or diabetes mellitus
￿ Intervention (aspiration or surgical) targeted at
hepatic or renal cysts within three months of
baseline
￿ Treatment with somatostatin analogues within 3
months of baseline
￿ Mental illness that interferes with the patient abil-
ity to comply with the protocol
￿ Drug or alcohol abuse within one year of baseline
￿ Increased liver enzymes (2-fold above normal
values); exception is an isolated elevated gamma-glu-
tamyltransferase or alkaline phosphatase, which
occurs frequently in polycystic liver disease
￿ Co-medication with known interaction with lan-
reotide, like cyclosporine
Exclusion criteria for the use of iodine based radiocontrast
￿ Use of nephrotoxic agents like NSAIDs or diuretics
within 24 hours before receiving a contrast-
enhanced CT-scan
￿ History of moderate or severe reaction to contrast
injection
￿ History of contrast induced nephropathy
￿ Treatment with I
131 during the course of the trial
￿ Diagnosis of Morbus Kahler or Morbus
Waldenström
*eGFR < 60 ml/min/1.73 m2 (MDRD formula)
Study design and setting
The RESOLVE trial is a single centre open label study in
subjects with ADPKD. The trial aims to enroll 43
ADPKD patients. The trial design is schematically repre-
sented in Figure 1. All eligible patients receive lanreotide
120 mg for a total of 24 weeks. At start and end of
treatment, total liver and kidney volumes are measured
by computer-tomography (CT) with contrast media if
eGFR (MDRD) is > 60 ml/min/1.73 m
2, or without con-
trast media if eGFR (MDRD) is 30-60 ml/min/1.73 m
2.
In addition, all patients are evaluated at 4 and 12 weeks
after start of treatment. Recruitment has started in July
2011, will last until July 2012 and will be completed by
July 2013. This study is submitted to clinicaltrials.gov
(NCT01354405).
Trial treatments
All patients will receive long-acting 120 mg Somatuline
®
(Lanreotide) administered deeply subcutaneously every 4
weeks (28 days for a total duration of 24 weeks).
Another trial documented the efficacy and safety of
administration of 120 mg lanreotide in patients with
polycystic liver disease and demonstrated that this
dosage is well tolerated in patients and there were no
notable drop-outs [8]. The most common adverse effect
are loose, pale and fatty stools which typically start 24
hours after the first injection of lanreotide and lasts for
1-4 days. Pancreas enzyme replacement is prescribed to
ameliorate these symptoms if they persist. In case of
lanreotide-associated toxicity, the dose will be reduced
with 30 mg until symptoms disappear. Lanreotide will
be administered at the patient’sh o m eb yad e d i c a t e d
nursing team.
Primary outcome
The primary outcome of the RESOLVE trial is to assess
the effect of lanreotide treatment on total liver volume
in ADPKD patients with symptomatic polycystic liver
disease. Primary efficacy endpoint is absolute change in
liver volume after 24 weeks of treatment with lanreotide
compared to baseline liver volume. We compare our
findings with the natural course of polycystic liver
growth observed in the trials that evaluated somatostatin
analogue treatment in PLD patients [6-8].
Secondary outcomes
The proportional change in liver volume (normalized as
percentage) from inclusion to week 24 will be assessed
as a secondary outcome. Furthermore, other secondary
outcomes are the change in total kidney volume and
that of 3 kidney tissue classes [15]. We will distinguish 3
kidney tissue classes on basis of CT images: cysts, par-
enchyma, and intermediate volume. Intermediate
volume represents regions with contrast enhancement
markedly lower than that of vascularized parenchyma
tissue but higher than that of cysts, and is correlated to
GFR decline [15,21]. In addition, changes in quality of
life (assessment with EuroQoL questionnaire) and gas-
tro-intestinal symptoms (using a gastrointestinal symp-
toms questionnaire) will be measured at baseline and at
end of treatment [22,23]. Renal function will be assessed
by using estimation equations (MDRD and cystatin C)
as well as measured creatinine clearance determined by
24-hour urine collection. The frequency and severity of
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to evaluate the safety and tolerability of treatment with
lanreotide. Finally, urinary biomarkers (NGAL, a1-
microglobulin, KIM-1, H-FABP, MCP-1) and serum
FGF23 will be assessed before and after treatment with
lanreotide [16,17]. These biomarkers are correlated to
parameters of ADPKD disease severity and may predict
treatment response to lanreotide. As concentration of
FGF23 in serum is dependent of vitamin D, parathyroid
hormone (PTH), calcium and phosphate serum levels,
these parameters will also be measured at start and end
of treatment.
Data collection
Data will be collected into a case record form designed
to capture all visit information including medical his-
tory, results from laboratory analysis and adverse events.
Study duration for all patients is 25-28 weeks in total,
divided in a 1-4 weeks screening phase and a 24 weeks
follow up phase after start of lanreotide (Figure 1). At
screening, a pregnancy test is performed (for women
with childbearing potential). Within the follow up phase
of the trial, patients are seen at week 0, 4, 12 and 24.
During each visit, medical history, adverse events, toler-
ability and drug accountability are assessed. In addition,
vital signs and weight are measured, blood samples are
drawn and the eGFR (MDRD) is estimated. Two main
study visits including CT volumetry (procedure
described below), questionnaires, 24 hour and spot
urine collection will take place at start (week 0) and end
of treatment (week 24). Furthermore, blood and urine
samples will be taken for assessment of serum FGF23,
PTH, Vitamin D, Cystatin C and the urinary biomarkers.
The requested parameters at the different visits are
listed below.
Screening
￿ Written informed consent
￿ Eligibility criteria check
￿ Estimated GFR (MDRD)
￿ General characteristics
￿ Concomitant therapy and medical history
￿ Physical examination and vital signs
￿ Laboratory tests: haematology, biochemistry and
lipid profile
￿ Pregnancy test in females between 18-50 years
Baseline (week 0) and end-of-treatment (week 24)
￿ CT liver and kidney volumetry
￿ Estimated GFR (MDRD and Cystatin C clearance)
￿ Creatinine (24-hour urine)
￿ Urinary biomarkers: NGAL, a1-microglobulin,
KIM-1, H-FABP, MCP-1 and creatinine (spot urine)
￿ FGF23 (serum and spot urine)
￿ Vitamin D, PTH, calcium and phosphate (serum)
￿ GI symptom questionnaire
￿ EuroQol questionnaire
Every visit
￿ Adverse events and concomitant therapy
￿ Drug accountability
￿ Physical examination and vital signs
￿ Weight
￿ Estimated GFR (MDRD)
￿ Laboratory tests: hematology, biochemistry and
lipid profile
CT Scanning and 3-Dimensional Volumetry
CT scans at baseline and week 24 will be performed
on a multidetector CT scanner (Somatom Sensation 16
or 64; Siemens Medical Solution AG, Erlangen, Ger-
many). All CT scans are blinded to patient identity
and date of birth as well as date of scan. The effect of
lanreotide will be evaluated by 3D total liver and kid-
ney volume measurement of CT scan slices using Pin-
nacle
3® version 8.0 g (Philips, Eindhoven, The
Netherlands). Imaging protocol includes that CT scans
have a slice thickness of 3 mm, and liver and separate
kidneys will be outlined manually every 9 mm. The
software interpolates the intermediate slices and calcu-
lates the areas within the indicated circumference, and
finally, total liver or kidney volume. The vessels and
the ureter in the area of the renal hilum are excluded
from manual volumetric marking. Unblinding of CT
scans will be performed after all liver and kidney
volumes are measured.
Intermediate volume identification on CT images
Intermediate volume will be assessed as described ear-
lier [21]. Briefly, the kidneys will be outlined manually
on all acquired digital images using interactive image
editing software (GIMP; GNU Image Manipulation
Software, http://www.gimp.org). Subsequently, as an
image enhancement step, anisotropic diffusion filtering
will be used to smooth high-frequency noise [21]. Bin-
ary masks generated from the image outlines will be
applied to the enhanced images, and image segmenta-
tion will be applied to the resulting kidney regions
using a statistical approach known as Otsu’s threshold-
ing [24]. After the application of Otsu’sm e t h o dw i t ha
number of classes equal to 4, each voxel in the volume
will classified as fat, cyst, intermediate, or parenchyma.
From the segmented images, cyst, intermediate, and
parenchymal volumes will be computed by multiplying
the voxel count of each class by voxel volume, as
determined by the acquisition protocol [21]. Validation
of the segmentation procedure is described previously
[21].
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Patients will be withdrawn from the study for any of the
following reasons: withdrawal of informed consent,
pregnancy, failure to adherence to protocol require-
ments, unacceptable toxicity, surgical intervention dur-
ing the trial and if the investigators conclude that it is
in the patient’s best interest for any reason. There will
be no option of replacement into the study after
withdrawal.
Sample size considerations
A previous trial suggested that 6-month treatment with
lanreotide induced a 134 ml decrease in total liver
volume in polycystic liver patients [8]. For the purpose
of this study we assumed that lanreotide is able to resort
in a similar effect in patients with exclusively ADPKD. A
sample size of 39 will achieve 80% power to detect a dif-
ference of 150.0 mL (SD 325.0 ml) in liver volume (pre
versus after treatment) using a two-sided a-level of 0.05.
Taken into account a dropout rate of 10%, the sample
size has to be 43 for the complete cohort.
Statistical analysis
All outcomes will be analyzed on an intention-to-treat
basis. Parallel analyses conducted on per-protocol popu-
lation will be performed. The volume of the liver will be
determined as mentioned before. For primary and sec-
ondary endpoints, absolute and relative differences
between baseline and end of treatment will be analyzed
using a paired two-sided t-test, or Wilcoxon ranked sum
test where appropriate. All statistical analyses will be
two-sided with a critical significance level of 5%.
To evaluate which biomarkers predict treatment
response to lanreotide, the association between each bio-
marker (NGAL, a1-microglobulin, KIM-1, H-FABP,
MCP-1 and FGF23) and each of the primary and second-
a r yo u t c o m e sw i l lb ee x a m i n e db yu n i v a r i a t el i n e a r
regression analyses. Predictors that are univariately asso-
ciated with the outcome (p-value < 0.10) will be included
in multivariate linear regression analyses. The model will
be reduced by excluding predictors from the model with
a p-value of > 0.05. In addition, the following variables
will also be included in univariate models as predictors of
favorable outcome as a secondary analysis: age, baseline
liver volume, baseline kidney volume, kidney intermedi-
ate volume and estimated renal function (MDRD and
cystatin C). All abnormal laboratory results will be listed
and frequency tables will be compiled for Adverse Events
classified according to the standard WHO-ART Body
System Dictionary and preferred terms.
Ethical considerations
Ethical approval has been obtained from the local ethics
committee of the Radboud University Nijmegen Medical
Center. This study will be performed in accordance with
the protocol, the guidelines of Good Clinical Practice/
ICH, the principles of the Declaration of Helsinki 1964
as modified by the 52
nd WMA General Assembly, Edin-
burgh, Scotland, October 2000 including two notes of
clarification paragraph 29 and 30, and the local national
laws governing the conduct of clinical research studies.
All subjects have the right to withdraw from the study
at any time during the trial. Safety of trial subjects is
monitored by an independent data safety monitoring
board (DMSB).
Discussion
Treatment with lanreotide may results in several iden-
tifiable benefits for ADPKD patients with polycystic
liver disease. It may map the road to a causal therapy
for patients with polycystic liver disease. Current surgi-
cal procedures carry the risk of considerable morbidity
and not all patients are qualified for this approach.
Alternative options are needed and our trial will estab-
lish whether and to which extent and in whom lanreo-
tide treatment can reduce liver volume growth in
ADPKD.
The main strength of the RESOLVE trial is to deter-
mine whether lanreotide decreases liver volume in
patients with ADPKD. Another group performed a post-
hoc analysis of data from a randomized, cross-over
study in 12 patients with ADPKD [25]. In this analysis,
they evaluated the effect of octreotide in 12 ADPKD
patients with polycystic livers and found a beneficial
effect on liver volume [6]. However, these findings must
be taken with caution due to the small sample size and
because carry over effects cannot be excluded given the
cross-over design. This will be the first trial that is pow-
ered to detect a small but significant change in polycys-
tic liver volume in ADPKD patients treated with
lanreotide. Furthermore, although we predetermined
renal volume and renal function as a secondary out-
come, the inclusion of exclusively ADPKD patients
allows us to evaluate an effect of lanreotide on kidney
volume and function. Third, intermediate volume is
tightly connected to the decline in GFR and might be
useful as a marker for ADPKD progression [15]. In this
trial, we will investigate whether lanreotide has a benefi-
cial effect on intermediate volume. Fourth, it is still
unknown which patient factors predict treatment
response to somatostatin analogues. Urinary and serum
biomarkers associated with ADPKD disease severity are
assessed in the RESOLVE trial at baseline and at end of
treatment [16,17]. We hope to correlate these markers
to treatment response as this will allow us to give evi-
dence based recommendations which ADPKD patients
will benefit specifically from treatment with lanreotide.
Finally, this design provides an opportunity to study the
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matic polycystic liver disease.
There are limitations that come with our study worth
addressing. First, as we seek polycystic liver targeting,
ADPKD patients with symptomatic polycystic livers and
only mildly enlarged polycystic kidneys are not excluded
from the RESOLVE trial. To properly evaluate the effect
of lanreotide on polycystic kidney volume, we should
have introduced a minimal threshold of total kidney
volume. Second, we do not include a control arm in our
trial, but rather sought comparison with values at base-
line. This prevents us from direct comparison with
untreated ADPKD patients. However, based on our
observations and the data from placebo arms of other
randomized clinical trials, it is possible to establish the
natural course of symptomatic polycystic liver disease.
In our original trial, an increase of 1.6% in liver volume
was observed after 6 months, while in another trial liver
volume increased with 0.9% after 12 months [7,8]. Both
these trials included a mixture of APDKD and PCLD
patients. Liver volume increased with 1.2% during 6
months in a third trial that included exclusively ADPKD
patients [6]. As the natural growth pattern of polycystic
liver disease does not seem to differ between ADPKD
and PCLD, we may use the data from these placebo
arms to evaluate if lanreotide affects the growth of poly-
cystic liver volume. In addition, the lack of a control
group guarantees that a possible effective therapy is not
withheld from symptomatic PLD patients included in
the trial, and that the results will be directly applicable
to ADPKD patients in the daily practice.
Despite these limitations, our study will add valuable
information to the literature of medical treatment of
polycystic liver disease.
In conclusion, by designing the RESOLVE trial, we
anticipate that lanreotide is an effective therapeutic
option for ADPKD patients with symptomatic polycystic
livers, and we hope to identify patient related factors
that predict treatment response.
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